|
| Monday, 27 July 2020, 17:28 HKT/SGT | |
| |
|
|
|
|
开发专门用作新型冠状病毒检测的移动核酸检测实验室
交付予上海浦东机场作入境检测 |
香港, 2020年7月27日 - (亚太商讯) - 全球具领导地位的集装箱制造商及物流服务经营者 - 胜狮货柜企业有限公司（「胜狮」/「集团」）（股票编号：716）今天宣布，集团于二零二零年七月八日交付一台用作新型冠状病毒检测的移动核酸检测实验室予上海浦东机场。有关实验室设有三个功能部份，包括试剂制备室、样本处理室及核酸检测室，每日可处理最多1,500个样本。入境检测将于本周开始。
移动核酸检测实验室由集团位于中国上海的内部研发团队联同享负盛名的中国科学院专家及中国海关共同研发。集团研发团队的工程人员专注研发先进定制特种集装箱，以满足社会需要及全球客户的需求。除提供主要作运输用途的特种集装箱外，集团的研发团队亦开发应用于(包括但不限于)发电、储能、数据中心、住屋及酒店、正压防爆、农业养殖、科学及医药等多元范畴及用途的集装箱。
胜狮主席张松声先生表示：「我们对成功为上海浦东机场研发移动核酸检测实验室深感兴奋，并谨此感谢当地政府委以重任。集团在发展特种集装箱业务的过程中将结合现代化先进技术，以开发能满足不同行业之不同需要的产品。凭借研发团队的努力、卓越的生产技术，以及客户的信任，集团至今已成功开发超过1,000种特种产品。展望未来，我们已准备就绪，加强产品创新及提供多元化产品种类以满足社会特定需要。」
关于胜狮货柜企业有限公司
胜狮为全球具领导地位的集装箱制造商及物流服务经营者之一。集团的制造业务涵盖在中国经营的集装箱厂房，专注干集装箱及特种集装箱的制造、研发及销售。而物流业务则包括经营位于中国重要位置及香港的集装箱堆场，以及在厦门经营物流公司。凭借周全的投资策略，集团正逐步迈向业内的市场领导位置。详情可参阅: www.singamas.com。
话题 Press release summary
部门 金融, 业务
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
|
|
Latest Press Releases
Operations Started for the Nagaoka Methanation Demonstration Utilizing the CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates
Thursday, June 4, 2026 10:49:00 PM
|
|
|
Fujitsu and Daiichi Life Group Launch Joint Research to Advance Asset Management with Quantum Technology
Thursday, June 4, 2026 10:17:00 PM
|
|
|
"Making Children and Adults Smile:" Honda Launches the SMILE RIDER PROJECT
Thursday, June 4, 2026 9:46:00 PM
|
|
|
SnowValley Secures New Partnerships Across Major Global Food Exhibitions in H1 2026, Steadily Expanding Its International Business 
June 4, 2026 21:36 HKT/SGT
|
|
|
Using Personal Loans Wisely to Improve Your Money Situation in Singapore
June 4, 2026 21:35 HKT/SGT
|
|
|
GR Premiers GRMN Corolla
Thursday, June 4, 2026 9:05:00 PM
|
|
|
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market
June 4, 2026 20:43 HKT/SGT
|
|
|
Island States Ocean Summit Opens in Tokyo
Thursday, June 4, 2026 11:00:00 AM
|
|
|
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
June 4, 2026 09:00 HKT/SGT
|
|
|
Mazda and Nippon Express Launch Demonstration Trial Using Biodiesel Fuel
Wednesday, June 3, 2026 11:26:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
